19 Promis Title - 25 Dec 2023 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role: 10%+ Owner
Signature: Title 19 Promis By: /s/ Michael S. Gordon, Manager
Issuer symbol: PMN
Transactions as of: 25 Dec 2023
Net transactions value: $0
Form type: 3
Filing time: 27 Dec 2023, 06:03:52 UTC
Next filing: 02 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PMN	Common Shares, no par value						1,110,513	25 Dec 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PMN	Warrants to Purchase Common Shares, no par value							25 Dec 2023	Common Shares	51,562		Direct	F1
holding	PMN	Warrants to Purchase Common Shares, no par value							25 Dec 2023	Common Shares	26,597		Direct	F2
holding	PMN	Warrants to Purchase Common Shares, no par value							25 Dec 2023	Common Shares	797,872		Direct	F3
holding	PMN	Series 2 Preferred Shares, no par value							25 Dec 2023	Common Shares	500,000		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of 51,562 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $0.21 per whole warrant. These warrants are currently exercisable and expire on August 24, 2026.
F2	Consists of 26,597 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
F3	Consists of 797,872 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $1.75 per whole warrant beginning February 23, 2024. These warrants expire on February 23, 2029, the fifth anniversary of the date the warrants first become exercisable.
F4	The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $14 million.